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1. Introduction 
Type 2 diabetes and hypertension are becoming a major worldwide health problem, besing 
associated with increasing prevalence of obesity and excess morbidity and mortality. 
Furthermore, hypertensive patients with diabetes or obesity are more predisposed to target 
organ damage, resulting stringent targets for blood pressure control [1-4]. Focusing on the 
close associations between obesity, hypertension and diabetes, the NHANES [5, 6] and the 
Behavioral Risk Factor Surveillance System (BRFSS) [7] studies showed very close 
relationships between the prevalence of obesity, hypertension, and diabetes (Figure 1). The 
Framingham Heart Study [8] demonstrated that diabetic subjects were at 2-fold higher risk 
mortality, comprising both cardiovascular and non-cardiovascular mortality. Evidence from 
these epidemiological studies indicates that obesity and weight gain are associated with an 
increased risk of hypertension [5-7, 9] and type 2 diabetes [7, 9, 10], and that intentional 
weight loss reduces the risk that currently overweight individuals will develop 
hypertension [11, 12] or type 2 diabetes [13] . 
The clustering of cardiovascular risk factors associated with (abdominal) obesity is well 
established.  Type 2 diabetes, itself, contributes strongly to mortality, morbidity, and 
cardiovascular risk, including myocardial infarction [14], cardiac events [15-18], stroke, 
atherosclerosis [19-21] and cardiovascular and renal complication [22, 23].  Hypertension is 
observed twice as frequently in diabetic patients than in the general population, and its 
prevalence is higher in type 2 diabetes than in type 1 diabetes. Diabetes accompanying 
cardiovascular diseases such as hypertension is associated with higher mortality and 
morbidity [24]. The World Health Organization Multinational Study of Vascular Disease in 
diabetes [17, 18] showed that even in the absence of proteinuria and hypertension, 
standardized mortality rates were significantly higher in patients with both type 1 and type 
2 diabetes compared to those in the general population. Standardized mortality was higher 
in those with type 1 diabetes compared with type 2 diabetes. Both hypertension and 
proteinuria in diabetes were associated with a markedly high mortality risk by 11-fold for 
men with type 1 diabetes, and 5 fold for men with type 2 diabetes. A longer duration of 
diabetes and hypertension was a stronger predictor of mortality among diabetic and 
hypertensive patients. Therefore, those hypertensive patients with concomitant diabetes 
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mellitus, or strong lifestyle or dietary factors to predict the development of type 2 diabetes 
such as obesity, should be treated as a matter of priority in order to prevent subsequent 
cardiovascular complications [25]. Importantly, the blood pressure goals of antihypertensive 
treatments is much lower in hypertensive patients with diabetes (<130/80 mmHg) 
compared to hypertensive patients without complications [1, 4] (Table 1). 
 
 
Fig. 1. Increased prevalence of diabetes and hypertension. [Reference 7] 
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Clinic blood 
pressure 
Home blood 
pressure 
Young/middle-aged persons <130/85 mmHg <125/80 mmHg 
Elderly persons <140/90 mmHg <135/85 mmHg 
Diabetic patients with kidney disease <130/80 mmHg <125/75 mmHg 
Diabetic Patients after myocardial 
infarction 
   <130/80 mmHg    <125/75 mmHg 
Diabetic patients with cerebrovascular 
disorders 
<140/90 mmHg <136/85 mmHg 
Note: As the criteria for hypertension include a clinic blood pressure (BP) of 140/90 mm Hg and a home 
BP of 135/85 mm Hg, the differences between clinic and home BP (5 mm Hg) were simply applied to 
the clinic BP in each condition and derived provisional target home BP levels.BP, blood pressure. 
[Reference 2] 
Table 1. Expected target blood pressure levels of antihypertensive treatment 
The selection of the most suitable pharmacological treatments for those hypertensive 
patients with type 2 diabetes is governed to a degree by the knowledge of the physiological 
mechanisms underpinning the specifics of the conditions. Insulin resistance, stimulated 
renin-angiotensin-aldosterone system (RAAS), sympathetic nervous activation, and leptin 
resistance (hyperleptinemia)  [26-29] are observed very frequently in type 2 diabetes, 
hypertension and obesity, and these factors appears to play an important role on the onset 
and developments of these conditions [23, 30, 31).    
The first line of treatments for obesity, type 2 diabetes, and hypertension are weight loss 
with a lifestyle modification such as low caloric diet and exercise [32-34], or, in those with 
more severe obesity or inability to undertake an exercise program, or bariatric surgery. 
Perhaps the most important and difficult aspect in controlling obesity is avoiding weight 
regain [35, 36]. Anti-obesity drugs such as orlistat, sibtramine, rimonabant, and contrave [37-
40] have been developed, however these drugs were recently withdrawn from the markets 
in Europe, the United States and Australia due to serious side effects. Additionally, leptin 
administration (pegtlatyed recombinant leptin, PEG-OB; recombinant methionyl human 
leptin, r-metHu Leptin) has been investigated for effects of weight loss and their 
mechanisms, however, it has not yet been used clinically.    
Despite the benefits of lifestyle modifications, additional pharmacological treatment for the 
management of hypertension is frequently needed. However, the choice of an 
antihypertensive drug is controversial for patients with associated with diabetes. Lind et al. 
[41] have previously summarized these metabolic effects with long-term antihypertensive 
treatments. Studies suggest that treatment with different antihypertensive drug classers may 
have varied effects on glucose and lipid metabolism [42]. In this context, it would be 
important to choose more beneficial antihypertensive drugs that have less adverse metabolic 
effects and to achieve stricter blood pressure goals for hypertension associated with type 2 
diabetes and obesity.  
An integrated cardiovascular risk management approach should be adopted. Aggressive 
blood pressure control is important, particularly in patients at high cardiovascular disease 
risk such as those with diabetes. Moreover, well-tolerated antihypertensive agents with 
protective benefits beyond blood pressure lowering, if this can be achieved, should be 
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adopted [43]. Recently, many large scale clinical studies have shown that angiotensin II 
receptor blockers (ARBs) and angiotensin converting enzyme inhibitors (ACE inhibitors) are 
highly efficacious, well-tolerated antihypertensive agents [44, 45]. More disputed is whether 
there are additional benefits, beyond blood pressure lowering, leading to greater 
cardiovascular protection in obesity-related hypertension, metabolic syndrome, and 
diabetes. Recently, renin-inhibition with Aliskiren has been reported to impart an 
ameliorative effect on insulin resistance in type 2 diabetic mice [46]. Calcium channel 
blockers (CCBs), especially newer longer-acting dihydropyridines, may also provide 
favourable metabolic effects by improving insulin sensitivity and stimulated RAAS and 
sympathetic nervous activation in diabetes patients [47-49].  
In this review, we discuss i) mechanisms of hypertension in type 2 diabetes; ii) the importance 
of weight loss as a non-pharmacological treatments for type 2 diabetes and hypertension; iii) 
achieving blood pressure reduction goals for hypertension with diabetes (JNC-7 and JSH 
2009), and iv) pharmacological treatments for hypertension in type 2 diabetes.  
2. Characteristics of hypertension in obesity and type 2 diabetes: insulin 
resistance, elevated sympathetic nervous activity, and stimulated the renin-
angiotensin-aldosterone system (RAAS) (Figure 2) 
 
 
Fig. 2. Relationships between insulin resistance, sympathetic activation and stimulated renin-
angiotensin-aldosterone system (RAA) in type 2 diabetes and hypertension. [Reference 22]  
↑RAA ↑Leptin 
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Data from many epidemiological and clinical studies has identified a  close relationship 
between elevated sympathetic nervous system activity and insulin resistance / 
hyperinsulinemia in obesity (Figure 2) [22, 30, 50]. Several studies of longitudinal design 
have examined the effect of body weight changes (weight loss or weight gain) on 
sympathetic nervous system activity and insulin sensitivity (fasting plasma insulin levels 
and homeostatic model assessments of insulin resistance (HOMA-IR)). Elevations in 
sympathetic nervous activity and insulin levels during weight gain [51, 52] and reductions 
of sympathetic nerve activity and insulin levels during weight loss [11, 33, 53] have been 
observed. These longitudinal studies have clearly shown that elevated sympathetic activity 
and insulin resistance are closely linked to obesity (weight gain), the onset of obesity and the 
maintenance of obesity. Similarly, sympathetic activation and insulin resistance are strongly 
linked to the onset and development of hypertension [51, 52] and diabetes [54]. 
Furthermore, stimulation of the renin-angiotensin-aldosterone system (RAAS) is frequently 
demonstrated in obesity and hypertension [55, 56], and may be related to insulin resistance 
either via direct or indirect mechanisms [57, 58].   
2.1 Insulin resistance  
Ferrannini et al. was the first investigator who reported insulin resistance or 
hyperinsulinemia in obese hypertensive patients [59, 60] as well as lean hypertensive 
subjects [61] over 20 years ago. They observed in obese subjects that the insulin response to 
oral glucose was twice as high in the hypertensive patients as in the normotensive subjects, 
yet the glucose incremental area was 3-fold higher in the former than in the latter, thus 
indicating more severe insulin resistance in obese hypertensive patients. In the hypertensive 
group, 2-hrs plasma insulin was strongly correlated with systolic BP levels [61]. In obese 
hypertensive patients, the occurrence of hypertension marks the presence of additional 
hyperinsulinemia and insulin resistance, independent of any impairment of glucose 
tolerance [60].  
The EGIR-RISC study (The European group for the study of insulin resistance: relationship 
between insulin sensitivity and cardiovascular disease risk) studied insulin resistance and 
cardiovascular disease risk in 1500 healthy, middle-aged individuals over a 3-10 year period. 
Glucose tolerance and insulin sensitivity were measured with using an oral glucose 
tolerance test and the euglycemic insulin clamp. The EGIR-RISC Study demonstrated the 
importance of insulin resistance in the development of cardiovascular disease and diabetes, 
and has implications for the development of prevention and treatment strategies [62]. The 
EGIR-RISC study’s documentation of strong relationships of blood pressure to both insulin 
action and circulating insulin levels is compatible with the distinct influences on BP by 
insulin resistance and compensatory hyperinsulinemia [63]. 
2.2 Stimulated renin-angiotensin-aldosterone system 
Angiotension II (Ang II) produced in vessel walls disrupts the regulation of physiologically 
active substances by impairment of endothelium cell function [56]. Ang II mediated 
production of reactive oxygen species (ROS) promotes growth factors, cytokines and 
chemotactic factors relating to atherosclerosis [65]. A high level of insulin, as occurs in 
insulin resistance states, induces the activation of the tissue RAAS in blood vessels and the 
heart, and leads to an overproduction of Ang II in these tissues [33, 58]. High levels of 
insulin directly activate the expression and production of angiotensin, cell growth through 
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the angiotensin I receptor and the conversion of Ang I to Ang II in vascular smooth muscle 
cells. Although the mechanisms leading to the initial activation of tissue Ang II in high-risk 
conditions such as type 2 diabetes and hypertension, RAAS blocking agents such as 
angiotensin converting enzyme inhibitors (ACE inhibitors) and Ang II receptor blockers 
(ARBs), inhibits the multi-factorial effects of Ang II and reduce the frequency of 
cardiovascular events as observed in the HOPE and LIFE studies [58, 66, 67].  The HOPE 
Study (the Heart Outcomes Prevention Evaluation study) showed that high plasma rennin 
activity is an independent predictor of major vascular events and mortality in a stable 
population of high-risk patients with atherosclerosis and/or diabetes [58]. The RAAS 
associated with insulin resistance and sympathetic nerve activation plays an important role 
of hypertension in type 2 diabetes.  
2.3 Sympathetic nervous activation  
Energy intake stimulates hyperinsulinemia and sympathetic nerve activity resulting in 
blood pressure elevation.. Insulin-mediated sympathetic nerve stimulation in obese 
subjects is a compensatory mechanism aimed at restoring the energy balance by 
increasing the metabolic rate [22, 30]. Masuo et al. [51, 52] have shown in a longitudinal 
study that heightened sympathetic nervous activity (as indicated by plasma 
norepinephrine levels) may be a prime mover for future weight gain and blood pressure 
elevations in originally nonobese, normotensive subjects, and that insulin resistance may 
be an ancillary factor. During weight loss studies, reductions in plasma norepinephrine 
followed by reductions in HOMA-IR were observed [33, 34, 53].  These observations 
show, at least, that the sympathetic nervous system activity associated with insulin 
resistances play a major role in the onset and development of hypertension with type 2 
diabetes associated with obesity.  
3. Treatments for obesity 
3.1 Lifestyle modification for weight loss  
Weight loss is recommended as the first-line treatment for obesity-induced hypertension 
and type 2 diabetes. The objective of treatment for obesity is both to reduce the high risk of 
cardiovascular events and to prevent the developments of hypertension and type 2 diabetes 
[68]. A limited number of epidemiological studies have shown that intentional weight loss 
and fat loss may reduce the all-cause mortality rate [69]. The US Diabetes Prevention 
Program [70]and the Oslo Diet and Exercise Study [71] have shown marked clinical benefits 
with lifestyle intervention, and modest weight loss, on the resolution of the metabolic 
syndrome  and type 2 diabetes . Cohort studies with lifestyle modifications  [72] and case 
control studies with bariatric surgeries [73, 74] provide some evidence that intentional 
weight loss has long-term benefits on all cause mortality in overweight adults. In a cohort of 
patients enrolled in a cardiac rehabilitation program, weight loss was associated with 
favourable long-term outcomes on the composite end-point of mortality and acute 
cardiovascular events (fatal and nonfatal myocardial infarction, fatal and nonfatal stroke, 
emergent revascularization for unstable angina pectoris, and congestive heart failure) [75]. 
Maintaining weight loss is often the greatest challenge, but, many clinical studies have 
demonstrated that weight loss associated with life-style modification adds to the efficacy of 
antihypertensive pharmacological treatment [11]. 
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Ribeiro et al. [76], Trombetta et al. [77] and Tonacio et al. [78] compared the blood pressure 
lowering effects and forearm blood flow between a low caloric diet and exercise, and they 
observed that only exercise significantly increased forearm blood flow. Recently, Straznicky 
et al. [79] and Masuo et al.[80 have shown that a low caloric diet and exercise exert different 
effects on insulin resistance, the RAAS, and sympathetic nervous activity in obese 
hypertensive subjects, even though similar weight loss were observed.  
3.2 Bariatric surgery  
Gastric bypass and adjustable gastric banding are the two most commonly performed 
bariatric procedures for the treatment of morbid obesity or obesity which is resistant to 
lifestyle modification such as a low caloric diet plus exercise. Dixon et al. [74] showed that a 
gastric banding induced  significant weight loss and resulted  in better glucose control and 
less need for diabetes medication than conventional approaches to weight loss and diabetes 
control in a randomized controlled study in obese subjects with recently diagnosed type 2 
diabetes. Nguyen et al. [81] and other investigators [82, 83] compared the effects on weight 
loss, mortality, morbidity and changes in quality of life in subjects with either gastric 
banding or gastric banding. The percent of excess weight loss at 4 years was higher in the 
gastric bypass group compared to the gastric banding group. Postoperative HOMA-IR 
correlated with % weight loss [84].  Concurrent with restoration of insulin sensitivity and 
decreases in plasma leptin were dramatic decreases in skeletal muscle transcript levels of 
stearoyl coenzyme-A desaturase and pyruvate dehydrogenase kinase-4 at 3 and 9 months 
after gastric banding and a significant decrease in peroxisome proliferation activated 
receptor-alpha-regulated genes at 9 months. Gumbs et al. [84] speculated that decrease in fat 
mass caused by bariatric surgery significantly affected circulating adipocytokines, which 
favourably impact on insulin resistance. Improvements in glucose metabolism and insulin 
resistance following bariatric surgery result in the short-term from decreased stimulation of 
the entero-insular axis by restricted calorie intake and in the long-term by decreased fat 
mass resulting changes in release of adipocytokines. Leptin levels drop and adiponectin 
levels rise following laparoscopic adjustable gastric banding, gastric bypass and 
biliopancreatic diversion. These changes correlate with weight loss and improvement in 
insulin sensitivity [84].  
All forms of weight loss surgery (bariatric surgery) lead to calorie restriction, weight loss, 
decrease in fat mass, improvement in insulin resistance and type 2 diabetes mellitus [84]. 
Left ventricular relaxation impairment, assessed by tissue Doppler imaging, normalized 9 
months after surgery [85]. Laparoscopic gastric bypass and gastric banding are both safe 
and effective approaches for the treatment of morbid obesity, but gastric bypass surgery 
seems to have better early weight loss and more rapid ameliorative effects on insulin 
resistance and adipocytokines, muscle metabolism and left ventricular function, however 
effects the long term effects with similar sustained weight loss are unknown.  
3.3 Pharmacological treatments for obesity (Orlistat, Sibtramine, and Rimonabant-
Currently withdrawn in Europe, United States and Australia) 
Pharmacological treatment for the management of obesity is primarily aimed at weight loss, 
weight loss maintenance and risk reduction. Anti-obesity agents decrease appetite, reduce 
absorption of fat or increase energy expenditure. Recently, anti-obesity drugs such as 
orlistat, sibtramine and rimonabant have been developed placed on markets, however, the 
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latter two were withdrawn from markets in Europe and in the United States due to serious 
adverse events including psychiatric and cardiovascular related concerns. Lorcaserin, 
taranabant, topiramate and bupropion with naltrexone are currently on phase III trials with 
demonstrated significant weight loss compared to placebo at more than 12 months. Some 
pharmacotherapies have also demonstrated clinical benefits without any side effects, 
however, further studies are required for a long-term safety [86].  Recently, contrave, a 
combination of two approved drugs of bupropio and naltrexone, completed Phase III trials 
with significant weight loss and was approved by FDA  in 2010, but FDA declined to 
approve contrive due to serious cardiovascular adverse events in 2011 [86]. Importantly, 
obesity is, at least, in part, determined by genetic backgrounds [87], suggesting that a 
genetic approach to limiting obesity may find a place in the future.  
3.4 Leptin administration (pegylated recombinant leptin; PEG-OB, and recombinant 
methionyl human leptin; r-metHu Leptin) 
Lejeune et al. [88], Hukshorn et al. [89] and Westerterp-Plantenga, et al. [90] investigated the 
effect of weight loss and dietary restraint during and following weekly subcutaneous 
pegylated recombinant leptin (PEG-OB protein) administration in overweight men. 
Although treatment with PEG-OB protein led to a significantly greater body weight loss, 
energy expenditure, and dietary restraint, weight regain (rebound) was faster and stronger 
in subjects treated with PEG-OB compared to placebo. Asakawa et al. [91] administrated 
leptin intraperitoneally for 5 days in ob/ob mice. Intraperitoneal leptin administration 
caused significantly body weight loss of 13.2%. Further, an additional ameliorative effect on 
anxiety was found with leptin administration. This finding, in ob/ob mice, appears not be 
relevant to the human condition. PEG-OB protein may theoretically work on human for 
weight loss, however, at this juncture there are few clinical studies available.  
4. Pharmacological treatments for the metabolic syndrome as a precursor of 
type 2 diabetes 
The metabolic syndrome, which may be considered to be the precursor of type 2 diabetes 
,increases the risk of cardiovascular and renal events in hypertension. It has been associated 
with a wide range of classical and new cardiovascular risk factors as well as with early signs 
of subclinical cardiovascular and renal damage. The National Cholesterol Education 
Program's Adult Treatment Panel III definition uses easily measured clinical findings of 
increased abdominal circumference, elevated triglycerides, low high-density lipoprotein-
cholesterol, elevated fasting blood glucose and/or elevated blood pressure. Three of these 
five are required for diagnosis. It should be noted that other definitions of metabolic 
syndrome focus more on insulin resistance and its key role in this syndrome [22] (Table 2).  
Metformin has been shown to be helpful in subjects with metabolic syndrome or diabetes 
[92].  Atabek et al. [93] examined whether metformin treatment for 6 months was effective in 
reducing body weight and hyperinsulinemia, whilst also ameliorating insulin sensitivity 
indices in 120 obese adolescents with hyperinsulinemia. Before treatment, there were no 
significant differences between the metformin group and control group in terms of 
anthropometric data,  metabolic parameters, and blood pressure levels. After metformin, 
there was a significant decline in body mass index, fasting insulin, 120 min insulin levels 
and HOMA-IR and a significant increase in the fasting glucose/insulin ratio. With regards 
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to insulin sensitivity indices between the metformin treated and control groups, the 
metformin group displayed  significantly improved metabolic control at the end of the 
study. These findings show the efficacy of metformin for obesity and insulin resistance 
(metabolic syndrome) in obese adolescents. While  metformin has also been shown to 
prevent weight gain and improve blood glucose levels in hypertensive patients who 
received combination therapy of calcium antagonist (nitrendipine) and beta-blocker 
(atenolol) [94], in combination with drugs blocking the rennin-angiotensin system (ACEI or 
ARB), metformin may be associated with lactic acidosis and acute renal failure in patients 
with reduced renal function [95].   
Whilst thiazolidinedione drugs (TZDs) may prove useful in the metabolic syndrome, or type 
2 diabetes, a large concern has been expressed over the cardiovascular risks associated with 
rosiglitazone and pioglitazone [96]. Hsiao et al. [97] performed retrospective cohort study of 
473,483 newly diagnosed patients with type 2 diabetes in order  to evaluate the associations 
between oral antihyperglycemics (TZDs including rosiglitazone and pioglitazone, 
sulfonylureas, and metformin) with myocardial infarction, congestive heart failure, angina 
pectoris, stroke and transient ischemic attack. The findings extend the evidence provided 
further support to data derived from clinical trials that suggested that the disadvantages or 
harm caused by TZDs, especially rosiglitazone, may outweigh their benefits in patients with 
type 2 diabetes due to high risk for cardiac events. In addition, although the glycemic 
efficacy of TZDs are comparable to metformin, adverse effects and higher costs make TZDs 
less appealing for initial therapy. Among the TZDs, based on cardiovascular safety data, 
pioglitazone is the preferred choice. In combination with metformin, pioglitazone may be 
particularly beneficial for patients with metabolic syndrome and diabetes. In those patients 
who are achieving glycemic goals and tolerating the therapy without apparent 
complications, rosiglitazone may be continued [97]. Pioglitazone, but not metformin, in 
patients with type 2 diabetes significantly reduced hepatic lipid and increased adiponectin 
independent of weight change [98].   
5. Pharmacological treatments for hypertension (Figure 3)  
Although diabetes mellitus is associated with increased risks of death and cardiovascular 
events, in the Framingham Heart Study much of this excess risk wass attributable to 
coexistent hypertension [99]. Tight control of blood pressure (BP) significantly reduces 
cardiovascular morbidity and mortality in hypertensive patients with diabetes. In the 
United Kingdom Prospective Diabetes Study [100], a 10 mmHg reduction in systolic blood 
pressure was superior to a 0.7% decrease in glycosylated haemoglobin A1c (HbA1c) with 
regards to reducing morbidity and mortality [101]. In the Hypertension Optimal Treatment 
Study [102, 103] , the risk of cardiovascular events was decreased by 51% in those patients 
with type 2 diabetes randomized to the lower BP level.  The HOT study demonstrated that 
monotherapy was successful in only 25-40% of patients, according to the target diastolic 
blood pressure in diabetic patients, and they wee needed at least 2 drugs, average 2.5-3 
additional antihypertensive drugs to control blood pressure. [104, 105].  Based on these 
findings, contemporary treatment guidelines recommend a target blood pressure of <130/80 
mmHg for patients with diabetes [106], however, evidence shows that most hypertensive 
patients with diabetes are very resistant to controlling hypertension and frequently require 
two or more types of antihypertensive medications in order to achieve blood pressure goals 
[103, 104, 107, 108].   
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Fig. 3. The Guideline for Hypertension Treatments by the Seventh Report of the Joint 
National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood 
Pressure (JNC-7) : Algorithm for Treatment of Hypertension [Reference 1] 
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Class differences in the effects of antihypertensive medications on metabolic indices may 
therefore be an important consideration when choosing treatment for hypertensive patients 
with type 2 diabetes. Prospective, randomized studies with antihypertensive drugs have 
demonstrated differences between classes of drugs regarding effects on insulin resistance. 
Treatment with some beta-blockers or high-dose diuretics may be associated with 
impairment in insulin sensitivity,  
 Principal Hypertension Treatment  
1. Treat to BP <140/90 mmHg or BP < 130/80 mmHg in patients with diabetes or 
chronic kidney disease 
2. Majority of patients will require two medications to reach goal. 
 Algorithm for Treatment of Hypertension 
 
 
Fig. 3. The Guideline for Hypertension Treatments by the Seventh Report of the Joint 
National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood 
Pressure (JNC-7) : Algorithm for Treatment of Hypertension [Reference 1] 
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whereas angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers 
(ARBs), renin inhibitors, and calcium channel blockers (CCBs) are ameliorative or neutral. 
The most pronounced improvements have been obtained with alpha1-blockers. In a recent 
study, data indicated that moxonidine, an imidazoline1 receptor agonist, was effective in 
lowering blood pressure and improving insulin sensitivity in insulin-resistant patients. In 
populations at high risk of diabetes development, it may be justified to select drugs that 
improve insulin sensitivity when treating hypertension in insulin-resistant individuals [109]. 
 The most important factor for choosing antihypertensive medications for hypertensive 
patients with diabetes is the prevention of the progression of renal damage [105, 110], which 
impacts drastically on mortality and morbidity in diabetic patients. Experience from clinical 
trials suggests that drugs that target the RAAS may have metabolic advantages over drugs 
such as beta-blockers and diuretics, but this conclusion has not been proved definitively. 
The number of antihypertensive medications needed for blood pressure control in patients 
with diabetes is largely dependent on the estimated glomerular filtration rate (renal 
function) rather than hyperglycemia control [110].  
5.1 Angiotensin-Converting Enzyme inhibitors (ACE inhibitors)  
The stimulation of the RAAS is a key factor in the development of hypertension in 
obesity. Pharmacological blockade of the RAAS not only improve blood pressure, but also 
has a beneficial effect on inflammation, oxidative stress, insulin sensitivity, glucose 
homeostasis, and resultant renal and cardio-protection. Several strategies are available for 
RAAS blockade, including angiotensin-converting enzyme inhibitors (ACE inhibitors), 
angiotensin II receptor blocker (ARBs), renin inhibitors (Aliskiren) and mineralocorticoid-
receptor blockers, which have been proven in the clinical studies to result in 
improvements in cardiovascular disease and chronic kidney disease outcomes. Likewise, 
while hypertension in obesity, metabolic syndrome or type 2 diabetes, benefits from 
therapeutic lifestyle change, recently, clinical and epidemiological studies have shown 
that ACE inhibitors and ARBs are highly efficacious, persistent and well-tolerated 
antihypertensive agents, due to their cardio-and renal-protective benefits [58, 66, 67] . 
Moreover they have further beneficial effects in preventing complications of obesity and  
diabetes, such as progression of diabetic nephropathy, metabolic syndrome.  Renin 
inhibitor may also exert favourable effects on insulin resistance [46]. In other words, the 
use of the RAAS blockers as initial treatment (both ARBs and ACEIs) in several 
cardiovascular, metabolic, obesity, and renal disorders (i.e. diabetes, ischemic heart 
disease, heart failure, and proteinuria) is now well-established.  
The Heart Outcomes Prevention Evaluation (HOPE) study established that the significant 
effect of ACE inhibition (ramipril) on cardiovascular morbidity and mortality occurred 
through mechanisms beyond pure blood pressure control [58, 66].  Additionally, a recent 
analysis from the Blood Pressure Lowering Treatment Trialist's Collaboration showed that 
ARBs-based and ACE inhibitors -based treatment regimens were comparable in terms of the 
odds ratio for stroke and heart failure, independent of blood pressure reduction [111]. There 
is an emerging body of evidence suggesting that a combination approach to RAAS blockade 
with an ARB and an ACE inhibitor may further improve cardiovascular outcomes compared 
with mono-therapy with either agent alone [67].  In addition, some but not all clinical 
studies have shown that ACE inhibitors exert a favourable effect on insulin resistance [41, 
49], lower plasma leptin, suppress the sympathetic nervous overactivity in obesity [11] and 
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provide renal protection especially in diabetic patients with renal injury [43]. The 
sympathetic inhibition, however, is much less than that achieved with centrally acting 
imidazoline anti-hypertensive agents. Therefore, ACE inhibitors have s been recommended 
for use in special patients such as those with obesity, metabolic syndrome, diabetes, renal 
injury, or high risk of cardiovascular disease before the developments of ARBs [112]. The 
Irbesartan/HCTZ combination therapy and  Blood Pressure Reductions in Diverse Patient 
Populations (INCLUSIVE ) trial [113, 114] showed comparable antihypertensive efficacy and 
tolerability regardless of BMI or diabetes status. 
5.2 Angitension II receptor blockers (ARBs) 
The Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial 
(ONTARGET) program compared the efficacy of the angiotensin II receptor blocker (ARB) 
telmisartan, the angiotensin-converting enzyme (ACE) inhibitor ramipril, and combination 
therapy with telmisartan plus ramipril for reducing cardiovascular events [115, 116]. The 
ONTARGET trial involved 25,588 high-risk cardiovascular or diabetic patients with organ 
damage and compared the effectiveness of telmisartan with that of ramipril and showed 
that the two drugs were 'therapeutically equivalent'. Telmisartan is now the only ARB with 
clinical trial evidence of cardiovascular protection equivalent to that of ramipril, which is 
widely regarded as the 'reference' drug for RAAS blockade in patients at increased 
cardiovascular risk [116, 117]. The ONTARGET program consists of 2 randomized, double-
blind, multicenter international trials: the principal trial, ONTARGET, and a parallel trial, 
Telmisartan Randomized Assessment Study in ACE-I Intolerant Patients with 
Cardiovascular Disease (TRANSCEND) [115]. Results of ONTARGET and the 
TRANSCEND have allowed us to better define the therapeutic approach in high-risk 
patients showing the favorable effects of either ramipril or telmisartan on blood pressure 
control and cardiovascular risk [115].  The results of the ONTARGET and TRANSEND 
studies in patients with high risk cardiovascular disease as well as a number of recent meta-
analyses of randomized trials comparing the efficacy and safety of ACE inhibitors to ARBs 
and their combination in patients with heart failure, hypertension, and chronic kidney 
disease focused attention on the RAAS.  
Emerging data from experimental studies indicates a variety of beneficial effects of 
telmisartan [118].  In addition to blocking the angiotensin II type 1 receptor, telmisartan 
activates the peroxisome proliferator-activated receptor (PPAR)-gamma, a well-known 
target for treatment of the metabolic syndrome and diabetes. Few studies have analysed 
intra-class differences in ARBs with respect to anti-diabetic or metabolic effects. Makita et al. 
[119] examined a prospective randomized study comparing a PPAR gamma-activating ARB 
(telmisartan) with a non-activating ARB (candesatrtan), to delineate the effects on metabolic 
factors associated with cardiovascular disease in 153 hypertensive patient with glucose 
intolerance. Telmisartan decreased body weight while increasing serum adiponectin levels 
in hypertensive patients with glucose intolerance. Candesartan did not achieve similar 
improvements in these patients. Among ARBs, telmisartan may have a greater impact on 
obesity-related diseases.   
5.3 Renin inhibitors 
Recent pharmaceutical developments have shown that direct inhibition ofrenin results in 
decreased angiotensin I and II production and decreased urinary aldosterone excretion. Like 
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ACE inhibitors and ARBs, treatment with a direct renin inhibitor increases plasma renin 
concentration, but unlike the other RAAS inhibitors, treatment with a direct renin inhibitor 
decreases plasma renin activity. This unique combination of effects on the RAAS makes a 
direct renin inhibitor an attractive option to combine with other antihypertensive agents for 
the management of hypertension and its comorbidities [124]. Aliskiren/hydrochlorothiazide 
(HCTZ) therapy provides substantial BP reductions and may thus be a useful treatment 
option for older patients with stage 2 hypertension [125].  Clinical studies [126-128] 
including the ACTION study [125] have shown that combining  aliskiren, with drugs 
representing each of the major classes of antihypertensive agents (thiazide diuretics, beta 
blockers, ACE inhibitors, ARBs, and CCBs) reduces blood pressure and improves markers of 
cardiovascular outcomes. Importantly, aliskiren had an ameliorative effect on insulin 
resistance in type 2 diabetic mice [46]. Persson et al. [129] investigated the effects of aliskiren 
on renal function and showed that aliskiren added to losartan reduced albuminuria and 
renal dysfunction and was well tolerated.  In patients with type 2 diabetes, hypertension 
and albuminuria, aliskiren improved proteinuria [130].  Recently, Gao et al. [128] compared 
the efficacy between aliskiren and ARBs (losartan, valsartan and irbesartan) in 10 reports 
comprising 3,732 subjects and found that systolic and diastolic blood pressure reduction 
were similar. Results of several ongoing randomized clinical trials should provide 
additional insights into the potential of therapeutic combinations that include aliskiren to 
improve cardiovascular morbidity and mortality in patients with hypertension and related 
comorbidities. These studies have provided some further insight into the most effective 
strategy to prevent the adverse effects of RAAS activation. These insights may however 
need to be modified as the results of new strategies to block/inhibit the RAAS become 
available [131].   
5.4 Calcium Channel Blockers (CCBs) 
Calcium channel blockers (CCBs), especially newer long-acting dihydropyridines, may 
provide favourable metabolic effects by improving insulin sensitivity [49, 132, 133] and 
dampening the RAAS and sympathetic nervous activation in diabetes patients [47-49].   
ACCOMPLISH (The Avoiding Cardiovascular events through COMbination therapy in 
Patients LIving with Systolic Hypertension) trial was designed in order to evaluate the 
indications for CCBs [108, 132-135]. The ACCOMPLISH study compare the cardiovascular 
outcomes between  combination of  ACE inhibitor (benazepril )/CCB (amlodipine) and ACE 
inhibitor (benazepril)/diuretic (hydrochlorothiazide, HCTZ) therapy in patients with 
hypertension and high risk of cardiovascular events. The primary end point of 
cardiovascular morbidity and mortality was reduced by 20% in the benazepril/CCB arm 
and was superior to benazepril/HCTZ during the 30 months-follow-up. For 2,842 diabetic 
patients at very high risk given previous cardiovascular or stroke events, benazepril/CCB 
had significantly lower prevalence of albuminuria or microalbuminuria compared to 
benazepri/HCTZ [108]. In the whole cohort, there were less coronary events including acute 
coronary events and revascularization in the group with the benazepril/CCB. Side effects 
were generally more frequent with CCB than with the HCTZ combinations. Furthermore, 
the  ACCOMPLISH study also showed that benazepril/CCB demonstrated a marked 
ameliorative effect on serum creatinine and end-stage renal disease than benazepril/HCTZ 
[135]. Therefore, the ACCOMPLISH study provided evidence indicating that ACEI/CCB 
combinations are more effective in selected high-risk patients than are ACEI/HCTZ 
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combinations [108, 132-135]. The AMANDHA Study [136] compared the effects on 
albuminuria between manidipine and amlodipine, as an additional medication on RAAS 
blockers.  Both manidipine and amlodipine decreased blood pressure values to a similar 
extent. Urinary albumin excretion was reduced by 65.5% with manidipine versus 20% with 
amlodipine (p < 0.01) at 6 months and 62.7 versus 16.6% (p < 0.01) at 18 months.  Thus, the 
addition of manidipine, but not amlodipine, resulted in a large reduction in the urinary 
albumin excretion rate despite similar blood pressure reductions [136].  
Wiener et al. [137] showed that a combined therapy with an ACE inhibitor (benazepril) 
and a CCB (amlodipine) over 12  weeks hadadditive benefits on large-vessel compliance 
at similar levels of blood pressure lowering, compared with monotherapy with an ACE 
inhibitor (enalapril) in hypertensive patients with type 2 diabetes (52% vs. 32%, P<0.05) 
[137]. In addition, sub-studies to The International Nifedipine GITS study,  Intervention as 
a Goal in Hypertension Treatment (INSIGHT), showed that nifedipine GITS was 
significantly more effective at preventing an increase in intima-media thickness in the 
carotid artery and significantly slowed the progression of coronary calcification, 
compared with diuretics, oamilozide,  which are frequently observed in diabetes and 
atherosclerotic c patients [138].  The results from INSIGHT support incorporating 
nifedipine GITS in the management of high-risk hypertensive patients to prevent 
atherosclerosis-related illness and death [138]. These observations suggest CCBs has an 
ameliorative effects on atherosclerotic damage. 
Interestingly, in the Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) trial, 
the risk of new-onset diabetes was reported to be 23% lower among patients initiating 
therapy with valsartan versus amlodipine [139]. Unadjusted absolute risks of diabetes were 
21.4 (95% confidence interval (CI) 18.9-24.3) and 26.3 (95% CI 24.3-28.3) per 1000 patient-
years for valsartan and amlodipine, respectively; the corresponding relative risk (RR) for 
valsartan was 0.82 (95% CI 0.70-0.94). The meta-analysis including 1.721 trials and 99,006 
patients showed that CCBs were associated with a reduced incidence of new-onset type 2 
diabetes (odds ratio 0.81; 95% confidence interval [CI] 0.73-0.90; p = 0.0001) compared with 
diuretic or beta-blocker therapy [140]. The reduction in new-onset type 2 diabetes was 
maintained when CCB were compared to only thiazide diuretics (OR 0.86; 95% CI 0.75-0.99; 
p = 0.0346). Thus, CCBs may have benefits for treatments for hypertension in type 2 diabetes 
due to an ameliorative effect on insulin resistance and reductions in new-onset of type 2 
diabetes.  
5.5 Imidazoline-receptor agonists (moxonidine) 
Class differences in the effects of antihypertensive agents on metabolic indices may 
therefore be an important consideration when choosing treatment for patients who exhibit 
these characteristics [109]. Moxonidine, which selectively targets imidazoline type-1 
receptors in the sympathetic vasomotor centres of the rostral-ventrolateral medulla, is an 
effective antihypertensive and has been reported to exert favourable metabolic effects in 
preclinical and clinical studies [141]. In obese hypertensive rats, chronic, but not acute, 
moxonidine treatment partially restored insulin sensitivity [142]. Moxonidine reduced blood 
pressure associated with insulin sensitivity in obese hypertensive patients [143]. Moreover, 
although moxonidine and amlodipine were associated with comparable reductions in blood 
pressure, only moxonidine significantly decreased sympathetic nervous activity, improved 
insulin resistance and reduced plasma leptin levels [144].  A small dosage of moxonidine 
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was effective to lowering blood pressure when it was used as a combination therapy with 
low-dose hydrochlorothiazides in hypertension with type 2 diabetes  [145].   
The MARRIAGE study (Moxonidine And Ramipril Regarding Insulin And Glucose 
Evaluation) has extended these preliminary observations by comparing the effects of 
moxonidine and the ACE inhibitor ramipril--and the combination of both drugs--on 
metabolic and haemodynamic parameters in patients with hypertension and impaired 
fasting glycaemia [146].   
Both moxonidine and rilmenidine, were shown to exert beneficial effects, not only on blood 
pressure, but also lipid (reducing free fatty acids, triglycerides) [147, 148] and carbohydrate 
metabolism (improving glucose tolerance), and neurohormonal parameters such as plasma 
levels of norepinephrine, leptin, BNP, and ANP [149].   
Moxonidine and rimenidine activates I1 receptors in the RVLM, reducing the activity of the 
sympathetic nervous system [150, 151]. These I1-agonists have been shown to produce 
pronounced and long-lasting BP reduction in different animal models of hypertension, 
including the spontaneously hypertensive rats [152, 153]. Blood pressure reduction with 
moxonidine is usually accompanied by a reduction in heart rate which, however, is of 
shorter duration and lesser magnitude compared to the blood pressure reduction. Chronic 
administration of moxonidine to SHRs causes normalization of the heart and kidney 
damage (myocardial fibrosis, capillarization, regressive changes in myocytes, ventricular 
arrhythmia, left ventricular hypertrophy and renal glomerulosclerosis) in parallel with the 
reduction of blood pressure [152, 153]. Direct injection of moxonidine into the vertebral 
artery of cats elicits a more pronounced fall in blood pressure compared with intravenous 
injection of an equivalent dose, indicating the centrally origins of the antihypertensive 
effects [153].  In addition, drugs of this class appear to have the capacity to favorably modify 
insulin sensitivity, which has particular relevance in the treatment of hypertensive diabetic 
patients and obese hypertensive patients who may be insulin resistant. In the hypertension 
accompanying maturity onset diabetes and obesity, with recent recommendations from 
advisory bodies setting lower BP goals, and with these lower targets often being reached 
only with combinations of antihypertensive agents, it is advisable that all drugs used in 
combination therapy exert a favorable, or at least a neutral effect on insulin resistance . 
Sharma et al. [154] showed the efficacy of moxonidine in treating hypertension in those with 
metabolic syndrome or obesity. A post-marketing surveillance study (CAMUS) involving 
772 obese hypertensive patients with hypertension with and without the metabolic 
syndrome was conducted in Germany. Approximately 50% of subjects had metabolic 
syndrome and patients were treated with moxonidine and followed for 8 weeks. Reductions 
in BP were similar between subjects with and without the metabolic syndrome (both from 
168/97 to 141/83 mmHg), but the BP reduction was particularly pronounced in patients 
with severe hypertension at baseline. The response rate (diastolic blood pressure < or =90 
mmHg or reduction > or =10 mmHg) of antihypertensive treatment with moxonidine was 
also similar (94.0% for all patients versus 93.8% for patients with metabolic syndrome). After 
8 weeks of treatment, patients achieved a mean weight loss of 1.4 kg, which was not 
surprisingly, particularly pronounced in obese patients. Moxonidine effectively reduced 
blood pressure in patients with the metabolic syndrome while simultaneously reducing 
body weight in obese patients. 
In a study examining 77 obese hypertensive patients, Haenni et al. [155] used the 
hyperinsulinemia euglycemic glucose clamp technique and observed that treatment with 
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moxonidine for 8-9 weeks significantly improved insulin sensitivity in insulin-resistant 
obese hypertensive patients, but not in insulin-sensitive obese hypertensive patients. 
Sanjuliani et al. [144] compared the responses of blood pressure, sympathetic nerve activity 
and plasma levels of insulin and leptin to moxonidine and amlopdipine treatment over a 24-
week period.  Blood pressure reductions were of similar magnitude between both 
treatments. Moxonidine significantly reduced arterial plasma epinephrine and 
norepinephrine concentrations, orthostatic venous plasma norepinephrine and plasma 
insulin and leptin levels 120 minutes subsequent to an oral glucose loading, whereas 
amlodipine did not change any of those parameters. This study clearly demonstrated a 
comparable reduction in blood pressure with both antihypertensive drugs, but the 
neurohormonal and metabolic effects were different between the antihypertensive drugs.  
5.6 Low dose diuretics  
Low-dose of diuretics as a first agent in treatment of patients with hypertension and 
diabetes is well documented and widely recommended [156-160]. This treatment has 
beneficial effects on both morbidity and mortality while, previous general concern on the 
negative impact of diuretics on the different lipid parameters and metabolic effects appear 
not justified as, all long-term studies with low-dose diuretics have not been shown to affect 
lipid and glucose profiles in a negative way [161-163]. Moreover, in studies of a year or 
more duration, diuretics have been shown to reduce cardiovascular risk  [145, 164-166].  
Very recently, it was reported that Chlorthalidone reduced cardiovascular events more than 
Hydrochlorothiazide, suggesting that Chlorthalidone may be the preferred thiazide-type 
diuretics for hypertension in patients at a high risk of cardiovascular risk such as in diabetic 
or obese patients [167].   
5.7 Combination therapies   
The clinical combination of hypertension and diabetes carries a particular poor diagnosis. 
Achievement of target blood pressure (<130/80 mmHg) in this patient category is crucial in 
decreasing premature morbidity and mortality. Thus, management of subjects with type 2 
diabetes and associated hypertension needs to be early and aggressive, and must utilize a 
global approach. Now, especially for hypertensive patients with diabetes and obesity, 
multiple-medications are common [168].   
6. Conclusions  
Hypertension and type 2 diabetes are frequently associated with obesity. Life style 
modification with diet and exercise remains the initial treatment. Many subjects, however, 
fail to normalize/lose body weight, to maintain their weight loss, to control hyperglycemia, 
or to normalize blood pressure. Although diabetes mellitus is associated with increased risk 
of death and cardiovascular or renal events, much of this excess risk is attributable to 
coexistent hypertension.  
Several large cohort trials have demonstrated that tight control of blood pressure 
significantly reduces cardiovascular morbidity and mortality and cardio-and renal 
complications in hypertensive patients with diabetes [101-103]. Based on these findings, 
contemporary treatment guidelines recommend a target systolic blood pressure/diastolic 
blood pressure of <130/80 mmHg for patients with diabetes, however, evidence shows that 
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most hypertensive patients with diabetes are very resistant to controlling hypertension and 
frequently require two or more types of antihypertensive medications to achieve blood 
pressure goals [103, 110].    
Class differences in the effects of antihypertensive medications on metabolic indices and 
renal protective effects may therefore be an important consideration when choosing 
treatment for patients who exhibit these characteristics. Hypertension in type 2 diabetes is 
characterized as insulin resistance, which is associated with cardiovascular morbidity and 
mortality, and cardiac- and renal complications.  Another important factor for choosing 
antihypertensive medications for hypertensive patients with diabetes is the prevention of 
the progression of renal damage, which impacts the mortality and morbidity in diabetic 
patients. While antihypertensive agents such as beta-adrenoceptor antagonists may worsen 
insulin resistance and impair glucose tolerance, ACE inhibitors or ARBs exert positive 
metabolic effects and renoprotection. Experience from clinical trials suggests the renal 
protective drugs that target the RAAS and CCBs and beneficial.  
This article provides a synthesis of current findings with non-pharmacological and 
pharmacological treatments for hypertension in type 2 diabetes. Treatment of hypertension 
in type 2 diabetes is important with regards to the prevention of cardiovascular 
complications. To this stage, the preferred antihypertensive drug classes are somewhat 
uncertain, and disputed, however, smaller dosage of each class of drugs might lead less side 
events. Currently a combination therapy with 2 or more different classes of antihypertensive 
drugs is recommended [1, 4, 168]. Use of ACEIs and ARBs as the initial treatment in 
hypertension in type 2 diabetes is usually advocated as these agents exert favourable effects 
on insulin sensitivity and provide renal protection. A strong case for wider use of CCBs and 
the imidazoline drugs (moxonidine, rilmenidine) can also be made  
There are many aspects of the pathogenesis, prevention and treatment of type 2 diabetes 
that still need to be uncovered before a complete strategy to reduce the ongoing epidemic 
and burden of type 2 diabetes may be offered. 
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